Organic Chemistry Methods TRIZ Cases

A pentacyclic fused polycyclic compound inhibits Dexter energy transfer in light-emitting elements.

Selective LSD1 inhibitor salts normalize gene expression and reduce cancer cell proliferation by targeting epigenetic regulation mechanisms.

Mixed solvent parameter changes convert metastable SCO-101 into non-hygroscopic crystal form I, resolving stability and preparation contradictions.

Novel organic compound improves luminous efficiency and lifespan while maintaining low driving voltage to reduce Joule heating.

A deuterated anthracene host and boron dopant structure in the emitting layer enhances blue pixel performance.

An organometallic compound with steric repulsion suppresses phenyl rotation to narrow the emission spectrum.

Chemical Formula 1 compounds with boron or phosphine oxide centers lower driving voltage and boost light emission efficiency in organic light-emitting devices.

Crystalline forms of (S)-afoxolaner enable enantiomeric purification via controlled solvent crystallization, eliminating desolvation steps.

Diamantane compounds resolve the trade-off between high drive voltage and low luminous efficiency by optimizing molecular structure.

A phenanthrene organic compound enhances light extraction efficiency in OLED devices.

Replacing polar bonds with non-polar structures prevents recrystallization, extending operational lifetimes while maintaining solution processability.

Selective crystallization isolates pure Form IV benzamide to prevent polymorphic interconversion and ensure consistent therapeutic efficacy.

Asymmetric spiro compounds inhibit crystallization in the second layer, lowering driving voltage and extending service life.

Spirobifluoreneamines deliver hole transport while maintaining high glass transition temperature and stability.

A light-emitting layer combines three specific compounds to optimize phosphorescent and host material interactions.

Novel organic compound improves phosphorescent emission layer luminous efficiency and lifespan while maintaining low driving voltage.

A novel Valbenazine dibesylate crystalline form exhibits enhanced stability and aqueous solubility.

An organometallic compound with specific ligands enhances blue light emission in the 430 to 480 nm range.

Novel dichloroacetate tromethamine salt forms stable white crystals through controlled neutralization and cooling in aqueous solvents.

A boron-based condensed cyclic compound enhances emission efficiency in light-emitting devices through specific molecular substitution.

Specific substitutions at positions 2 and 6 of the purinone core enhance oral bioavailability while maintaining high selectivity against DNA-PK.

A polycyclic compound in the emission layer enhances light emitting element performance.

Reactive crystallization produces stable fedratinib diHCl polymorphs to resolve scalability bottlenecks in myelofibrosis drug preparation.

Polycyclic amines modulate opioid receptors to treat pain and neurological disorders while reducing side effects like respiratory depression.

Multifunctional bridged tricyclic carbamoylpyridone compounds target multiple HIV enzymes to suppress viral replication while minimizing drug interactions.

Plate crystals of lithium styrene sulfonate dehydrate at room temperature, eliminating high-temperature drying costs and polymerization risks.

A fused polycyclic boron compound enhances light emitting efficiency in organic electroluminescence devices.

Covalent KRAS G12C inhibitors overcome EGFR resistance by targeting the mutant cysteine residue, enabling treatment for pancreatic and colorectal cancers.

Maintaining low chloride ion concentration prevents ruthenium catalyst sintering, sustaining activity and selectivity during long-term cycloolefin production.

Specific triazole compounds inhibit p97 ATPase activity to treat neurodegenerative disorders while minimizing side effects.

Hierarchical pore architecture increases contact area and suppresses byproduct formation during high-concentration ethanol conversion.

A reaction inducer facilitates carbon-carbon bond cleavage in fluorinated hydrocarbons during liquid phase synthesis.

A roxadustat and L-proline co-crystal structure improves dissolution rates while maintaining robust pharmaceutical formulation integrity.

Deuterium substitution in host materials balances blue and green unit lifespans, preventing biased color coordinates over time.

Hydrogenation reduction of compound C using a heavy metal catalyst and chiral inducer produces high purity lactam intermediate D.

Molecular sieves replace liquid acid dehydrating agents in ether synthesis, eliminating waste acid generation and reducing hydrogen fluoride consumption.

Triazolopyrimidine intermediate synthesis uses basic reagents to form key compounds without toxic catalysts.

Nitrogen-heterocyclic carbene linked to pyridine strengthens the C-Pt bond in organometallic compounds.

Crystalline tildacerfont oxalate salt improves bioavailability while resolving manufacturing complexity.

Immunoglobulin single variable domains bind nucleotide-binding domain 1 to raise melting temperature by 5°C and prevent proteasomal degradation.

Multi-tube heat exchangers transfer direct chlorination reaction heat to evaporate sodium hydroxide, reducing cooling water consumption.

Alpha-type tris-(2,3-epoxypropyl)-isocyanurate crystals prevent storage precipitation by maintaining 2% to 15% beta-type content for long-term stability.

Platinum or palladium organometallic compounds enhance carbon-carbon bond energy and intermolecular bonds in organic light-emitting devices.

Specific organic host compounds balance electron and hole transport to improve luminescence efficiency and device stability in red-emitting OLEDs.

A Formula I organometallic compound enables saturated color emission in organic light-emitting diodes through specific ligand coordination.